Table 2.
Baseline Characteristics of Individuals Contributing to the Analysis of Virological Suppression
| Characteristic | In Analysis n = 837 (%) | Missing Viral Load N = 83 (%) | P Value |
|---|---|---|---|
| Age at initiation (y) | |||
| Median age (IQR) | 34.3 (27.3, 46.5) | 29.5 (23.5, 41.6) | .02 |
| 16–29 | 290 (34.6) | 43 (51.8) | … |
| 30–39 | 246 (29.4) | 15 (18.1) | … |
| 40–49 | 133 (15.9) | 9 (10.8) | … |
| >50 | 166 (19.8) | 13 (15.7) | … |
| Missing | 2 (0.2) | 3 (3.6) | … |
| Sex | |||
| Female | 599 (71.6) | 48 (57.8) | .009 |
| Male | 238 (28.4) | 35 (42.2) | … |
| CD4 at initiation | |||
| Median (IQR) (cells/mm3) | 348 (227, 480) | 399 (235, 521) | .630 |
| ≤350 | 418 (49.9) | 37 (44.6) | … |
| 350–500 | 230 (27.5) | 20 (24.1) | … |
| >500 | 182 (21.7) | 22 (26.5) | … |
| Missing | 7 (0.8) | 4 (4.8) | … |
| Viral load (copies/mL) | |||
| Median (log copies/mL) | 4.6 (4.0, 5.2) | 4.6 (3.9, 5.2) | .818 |
| <10000 | 200 (23.9) | 22 (26.5) | … |
| 10000–100000 | 350 (41.8) | 36 (43.3) | … |
| >100000 | 285 (34.1) | 25 (30.1) | … |
| Missing | 2 (0.2) | 0 (0.0) | … |
| Adherence (%) | |||
| <95 | 126 (15.1) | … | … |
| ≥95 | 699 (83.5) | … | … |
| Missing | 12 (1.4) | … | … |
| Antiretroviral therapy regimen | .001 | ||
| TDF+FTC+EFV | 806 (96.3) | 73 (88.0) | … |
| TDF+3TC+EFV | 6 (0.7) | 2 (2.4) | … |
| AZT+3TC+EFV | 18 (2.2) | 3 (3.6) | … |
| D4T+3TC+EFV | 1 (0.1) | … | … |
| AZT+3TC+PI | 1 (0.1) | … | … |
| Missing | 5 (0.6) | 5 (6.0) | … |
Abbreviations: 3TC, lamivudine; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IQR, interquartile range; TDF, tenofovir.